bioAffinity Technologies receives Canadian patent allowance for CyPath Lung diagnostic

bioAffinity Technologies, Inc.

Canadian Patent Office allowed patent (No. 3,136,245) for method using flow cytometry and TCPP to detect lung cancer in sputum.
Patent protects CyPath Lung test, which showed 92% sensitivity, 87% specificity, 88% accuracy in clinical studies.
Patent follows recent Chinese patent award; expands international IP portfolio.
Lung cancer is leading cause of cancer death in Canada; ~31,000 diagnosed in 2024.
CEO Maria Zannes says patent validates diagnostic platform and supports shareholder value.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.